ondansetron has been researched along with Minimal Disease, Residual in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated how residual tumour burden after cytoreductive surgery was related to the occurrence of acute and delayed nausea and vomiting in 101 ovarian cancer patients receiving their first chemotherapy course." | 2.68 | Impact of tumour burden on chemotherapy-induced nausea and vomiting. ( Avall-Lundqvist, E; Börjeson, S; Fredrikson, M; Fürst, CJ; Hursti, TJ; Peterson, C; Steineck, G, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hursti, TJ | 1 |
| Avall-Lundqvist, E | 1 |
| Börjeson, S | 1 |
| Fredrikson, M | 1 |
| Fürst, CJ | 1 |
| Steineck, G | 1 |
| Peterson, C | 1 |
1 trial available for ondansetron and Minimal Disease, Residual
| Article | Year |
|---|---|
Impact of tumour burden on chemotherapy-induced nausea and vomiting.
Topics: Adolescent; Adult; Age Factors; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; C | 1996 |